Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease

Immunologic Research

Volumn 61, Issue 1-2, 2015, Pages 141-146

  Agmon Levin, Nancy ^a,b   Kopilov, Ron ^a   Selmi, Carlo ^c,d   Nussinovitch, Udi ^a,e   Sánchez Castañón, María ^f   López Hoyos, Marcos ^f   Amital, Howie ^a,b   Kivity, Shaye ^a,b   Gershwin, Eric M ^d   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Autoantibodies; Autoimmunity; Liver; PBC (primary biliary cirrhosis); Vitamin D

Indexed keywords

URSODEOXYCHOLIC ACID; VITAMIN D; BIOLOGICAL MARKER;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BONE MASS; CASE CONTROL STUDY; CHEMOLUMINESCENCE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; VITAMIN D DEFICIENCY; AGED; AUTOIMMUNITY; BIOPSY; BLOOD; COMPLICATION; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; AUTOIMMUNITY; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84925506848     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8594-0     Document Type: Article

References (40)

1. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377(9777):1600–9. doi:10.1016/S0140-6736(10)61965-4.
2. Hirschfield GM, Gershwin ME. Primary biliary cirrhosis: one disease with many faces. IMAJ. 2011;13(1):55–9.
3. Agmon-Levin N, Shapira Y, Selmi C, Barzilai O, Ram M, Szyper-Kravitz M, et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun. 2010;34(1):55–8. doi:10.1016/j.jaut.2009.08.009.
4. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25(3):298–310. doi:10.1055/s-2005-916321.
5. Uibo R, Kisand K, Yang CY, Gershwin ME. Primary biliary cirrhosis: a multi-faced interactive disease involving genetics, environment and the immune response. APMIS. 2012;120(11):857–71. doi:10.1111/j.1600-0463.2012.02914.x.
6. Kawata K, Tsuda M, Yang GX, Zhang W, Tanaka H, Tsuneyama K, et al. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. PLoS ONE. 2013;8(9):e74225. doi:10.1371/journal.pone.0074225.
7. Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I, et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun. 2009;33(3–4):178–82. doi:10.1016/j.jaut.2009.09.010.
8. Wang Q, Selmi C, Zhou X, Qiu D, Li Z, Miao Q, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun. 2013;41:140–5. doi:10.1016/j.jaut.2012.10.004.
9. Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med. 2013;11:101. doi:10.1186/1741-7015-11-101.
10. Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, Ram M, et al. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden. Exp Mol Pathol. 2012;93(3):386–90. doi:10.1016/j.yexmp.2012.09.012.
11. Leung PS, Wang J, Naiyanetr P, Kenny TP, Lam KS, Kurth MJ, et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun. 2013;41:79–86. doi:10.1016/j.jaut.2012.12.007.
12. Selmi C, Gershwin ME. The role of environmental factors in primary biliary cirrhosis. Trends Immunol. 2009;30(8):415–20. doi:10.1016/j.it.2009.05.006.
13. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12(10):976–89. doi:10.1016/j.autrev.2013.02.004.
14. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9(11):709–15. doi:10.1016/j.autrev.2010.06.009.
15. Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. IMAJ. 2010;12(3):174–5.
16. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y. Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol. 2013;45(2):256–66. doi:10.1007/s12016-012-8342-y.
17. Agmon-Levin N, Kivity S, Tzioufas AG, Lopez Hoyos M, Rozman B, Efes I, et al. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren’s syndrome. J Autoimmun. 2012;39(3):234–9. doi:10.1016/j.jaut.2012.05.018.
18. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sanchez-Castanon M, Lopez-Hoyos M, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev. 2011;10(8):490–4. doi:10.1016/j.autrev.2011.02.002.
19. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy EV, Danko K, et al. Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol. 2011;8(3):243–7. doi:10.1038/cmi.2010.73.
20. Agmon-Levin N, Blank M, Zandman-Goddard G, Orbach H, Meroni PL, Tincani A, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145–50. doi:10.1136/ard.2010.134817.
21. Hajas A, Sandor J, Csathy L, Csipo I, Barath S, Paragh G, et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev. 2011;10(6):317–24. doi:10.1016/j.autrev.2010.11.006.
22. Amital H, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7. doi:10.1136/ard.2009.120329.
23. Arnson Y, Itzhaky D, Mosseri M, Barak V, Tzur B, Agmon-Levin N, et al. Vitamin D inflammatory cytokines and coronary events: a comprehensive review. Clin Rev Allergy Immunol. 2013;45(2):236–47. doi:10.1007/s12016-013-8356-0.
24. Kowdley KV, Emond MJ, Sadowski JA, Kaplan MM. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol. 1997;92(11):2059–61.
25. Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology. 1982;83(1 Pt 1):103–8.
26. Munoz SJ, Heubi JE, Balistreri WF, Maddrey WC. Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology. 1989;9(4):525–31.
27. Guanabens N, Pares A, Marinoso L, Brancos MA, Piera C, Serrano S, et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol. 1990;85(10):1356–62.
28. Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol. 2001;96(9):2745–50. doi:10.1111/j.1572-0241.2001.04134.x.
29. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39(1–2):34–42. doi:10.1016/j.jaut.2011.11.005.
30. Polido-Pereira J, Rodrigues AM, Canhao H, Saraiva F, da Silva JA, Fonseca JE. Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review. Clin Rheumatol. 2012;31(2):385–9. doi:10.1007/s10067-011-1879-y.
31. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005;42(5):1194–202. doi:10.1002/hep.20907.
32. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17–23. doi:10.1136/annrheumdis-2013-203863.
33. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med. 2011;50(1):1–10.
34. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006;130(3):715–20. doi:10.1053/j.gastro.2005.12.029.
35. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–7. doi:10.1016/j.jhep.2011.02.031.
36. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology. 1988;95(3):787–92.
37. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010;51(4):1158–67. doi:10.1002/hep.23489.
38. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol. 2007;5(4):513–20. doi:10.1016/j.cgh.2006.10.015.
39. Verma A, Maxwell JD, Ang L, Davis T, Hodges S, Northfield TC, et al. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis. Osteoporos Int. 2002;13(8):677–82. doi:10.1007/s001980200092.
40. Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, et al. Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab. 2008;26(4):379–84. doi:10.1007/s00774-007-0833-1.